MAR 09, 2016 7:25 AM PST

Blood Screen Predicts Chances of Melanoma Relapse

WRITTEN BY: Xuan Pham
Image credit: Pixabay.com


Screening melanoma patients’ blood could allow doctors to predict chances of cancer relapse. According to a new study published in Cancer Discovery, researchers were able to track relapse events based on sequencing of tumor DNA that’s in the bloodstream. A blood test based on this discovery could offer doctors and patients a way to stay ahead of melanoma’s penchant to escape treatments.

One of the biggest challenges in treating melanoma, skin cancer, is the high probability of relapse after initial treatment success. In about 50% of melanoma cases, the cancer is caused by an activating mutation in the BRAF gene that signal cells to grow and divide uncontrollably. Patients who receive drugs that specifically inhibit BRAF initially respond quite well, but many of those patients inevitably suffer relapse as the cells adapt and acquire new mutations. In these situations, early detection of new mutation events could impact the outcome of patient survival.

Circulating tumor DNA (ctDNA), also known as cell-free tumor DNA, is genetic material that’s freely floating in the bloodstream of cancer patients. Dead tumor cells are the source of ctDNA, as when broken these cells release the tumor DNA into the patient’s blood. ctDNA represents a non-invasive cancer biomarker that can indicate the presence of disease. And because detection requires only a blood sample, the technique of using ctDNA for cancer diagnosis is often called “liquid biopsy."

In blood samples from seven advanced melanoma patients, researchers from the Cancer Research UK Manchester Institute found new mutation patterns in genes other than BRAF. Specifically, the ctDNA revealed mutations in oncogenes like NRAS and PI3K, which are involved in the cell division process. These new genetic mutations are cancer’s escape routes against drugs that only target the BRAF gene, thus enabling melanoma’s relapse.

"Being able to spot the first signs of relapse, so we can rapidly decide the best treatment strategy, is an important area for research. Using our technique we hope that one day we will be able to spot when a patient's disease is coming back at the earliest point and start treatment against this much sooner, hopefully giving patients more time with their loved ones. Our work has identified a way for us to do this but we still need to test the approach in further clinical trials before it reaches patients in the clinic," said Professor Richard Marais, lead study author and Cancer Research UK's skin cancer expert.   
      
A blood screen specific for melanoma relapse has not yet been developed for the clinic, but the researchers are optimistic “blood tests like these will help us to stay one step ahead in treating cancer.”

Additional source: EurekAlert!

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 13, 2021
Cardiology
Can a Ketosis Metabolite Act as a Biomarker for Cardiovascular Diseases?
APR 13, 2021
Can a Ketosis Metabolite Act as a Biomarker for Cardiovascular Diseases?
Quick and reliable diagnostics are the key to controlling many diseases, including cardiovascular disease. Biomarkers ar ...
JUL 15, 2021
Technology
Raman Spectroscopy Helps Track IBD Patient Response to Treatment
JUL 15, 2021
Raman Spectroscopy Helps Track IBD Patient Response to Treatment
While there have been multiple methods of evaluating whether a patient with inflammatory bowel disease (IBD) is respondi ...
JUL 27, 2021
Clinical & Molecular DX
Thumb-Sized Device Tells You if Your Breath Stinks
JUL 27, 2021
Thumb-Sized Device Tells You if Your Breath Stinks
People generally can’t smell their own breath. So, for individuals with halitosis—or bad breath—friend ...
AUG 03, 2021
Drug Discovery & Development
A pediatric-friendly drug to combat snail fever
AUG 03, 2021
A pediatric-friendly drug to combat snail fever
           Schistosomiasis, also known as Bilharzia or snail fever, is a disease  ...
AUG 17, 2021
Clinical & Molecular DX
Delays in Breast Cancer Diagnoses Among Black Women
AUG 17, 2021
Delays in Breast Cancer Diagnoses Among Black Women
Thanks to breakthrough diagnostic technologies, we can now catch the early warning signs of breast cancer much faster th ...
SEP 01, 2021
Clinical & Molecular DX
Will Childhood Cancer Survivors Go On to Have Broken Hearts?
SEP 01, 2021
Will Childhood Cancer Survivors Go On to Have Broken Hearts?
Patients are seven times more likely to have a heart attack or stroke than the general population after receiving treatm ...
Loading Comments...